IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1151-1175 out of 1382.

<< < 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 > >>

Public Release: 30-Mar-2016
Science Translational Medicine
Cancer gene drives vascular disorder
Two research teams have uncovered mutations in a well-known cancer gene that may drive the most common form of blood vessel abnormality, venous malformations, in some patients.

Contact: Science Press Package
scipak@aaas.org
202-326-6440
American Association for the Advancement of Science

Public Release: 30-Mar-2016
Science Translational Medicine
Cancer drug could treat blood vessel deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin, finds new research in mice led by UCL, Memorial Sloan Kettering Cancer Center in New York and the Bellvitge Biomedical Research Institute in Barcelona. The findings are published in two independent but complementary papers in Science Translational Medicine, led by UCL and MSK respectively.

Contact: Harry Dayantis
h.dayantis@ucl.ac.uk
44-203-108-3844
University College London

Public Release: 29-Mar-2016
American Journal of Clinical Oncology
For prostate cancer, more radiation may not improve survival
Increasing the total dose of radiation to patients with non-metastatic prostate cancer does not improve their long-term outcomes, according to a new study.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 29-Mar-2016
Cancer
Statement published on pairing smoking cessation with lung cancer screening
Smokers who are screened for lung cancer should be encouraged to quit smoking during their visit, according to a paper co-written by Benjamin A. Toll, Ph.D., of the Medical University of South Carolina. Citing the recent USPTF recommendation that heavy smokers undergo a yearly screening for lung cancer, the authors note USPTF does not provide specifics for how smoking-cessation treatment should be offered in conjunction with screenings. The article, published in Cancer, addresses specific recommendations.

Contact: Allison Leggett
leggett@musc.edu
843-792-0376
Medical University of South Carolina

Public Release: 29-Mar-2016
International Society for Microbial Ecology Journal
Another reason to break the habit: Smoking alters bacterial balance in mouth
Smoking drastically alters the oral microbiome, the mix of roughly 600 bacterial species that live in people's mouths. This is the finding of a study led by NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center to be published online March 25 in the ISME (International Society for Microbial Ecology) Journal.

Contact: David March
davidbmarch@gmail.com
212-404-3528
NYU Langone Medical Center / New York University School of Medicine

Public Release: 29-Mar-2016
Proceedings of the National Academy of Sciences
Nanoparticles deliver anticancer cluster bombs
Scientists have devised a triple-stage 'cluster bomb' system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor.
National Basic Research Program of China, National Natural Science Foundation of China

Contact: Quinn Eastman
qeastma@emory.edu
404-727-7829
Emory Health Sciences

Public Release: 29-Mar-2016
International Journal of Radiation Oncology • Biology • Physics
Study finds adaptive IGRT for bladder preservation clinically feasible
A prospective study examining a trimodality treatment approach in localized bladder cancer cases using adaptive image-guided, intensity-modulated radiation therapy (IG-IMRT) found that the bladder preservation rate at three years was 83 percent.

Contact: Erin Boyle
erin.boyle@astro.org
703-839-7336
American Society for Radiation Oncology

Public Release: 29-Mar-2016
Journal of the American Medical Informatics Association
New tool mines whole-exome sequencing data to match cancer with best drug
New tool interprets raw data of whole exome tumor sequencing to match cancer's unique genetics with FDA-approved targeted treatments.
National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 28-Mar-2016
Tobacco Control
Cigarettes cheaper than e-cigarettes in 44 of 45 countries studied
Combustible tobacco cigarettes cost less to purchase than equivalent amounts of electronic cigarettes (e-cigarettes) in 44 of 45 countries sampled around the world.
American Cancer Society

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society

Public Release: 28-Mar-2016
Cancer
Choosing to die at home does not hasten death for patients with terminal cancer
A large study from Japan found that cancer patients who died at home tended to live longer than those who died in hospitals.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 28-Mar-2016
Nature Biotechnology
Improved 'liquid biopsy' technique from Stanford enhances detection of tumor DNA in blood
People with cancer have tumor DNA in their blood. A new way to quiet background 'noise' in the blood sample allows researchers to sequence minute quantities of these molecules to improve diagnosis and treatment.

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center

Public Release: 28-Mar-2016
Nature Materials
CWRU researchers make biosensor 1 million times more sensitive
To provide oncologists a way to detect a single molecule of an enzyme produced by circulating cancer cells, physicists and engineers at Case Western Reserve University have developed an optical sensor, based on nanostructured metamaterials, that's 1 million times more sensitive than the current best available. The device proved capable of identifying a single lightweight molecule in a highly dilute solution.
Ohio Third Frontier Project Research Cluster on Surfaces in Advanced Materials, Doris Duke Charitable Foundation, MORE Center at CWRU, Case Comprehensive Cancer Center

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-534-7183
Case Western Reserve University

Public Release: 28-Mar-2016
Nature Medicine
New target makes end run against therapy-resistant prostate cancer
Researchers at UC Davis, in collaboration with the other institutions, have found that suppressing the nuclear receptor protein ROR-γ with small-molecule compounds can reduce androgen receptor (AR) levels in castration-resistant prostate cancer and stop tumor growth.
Bridge Program of UCD Research Office, US National Institutes of Health, US Department of Veterans Affairs, Office of R&D, National Natural Science Foundation, Key Basic Research Program of China, Howard Hughes Medical Institute, US Department of Defensef

Contact: Dorsey Griffith
dgriffith@ucdavis.edu
916-734-9118
University of California - Davis Health System

Public Release: 28-Mar-2016
Proceedings of the National Academy of Sciences
How cancer stem cells thrive when oxygen is scarce
Working with human breast cancer cells and mice, scientists at the Johns Hopkins University say new experiments explain how certain cancer stem cells thrive in low oxygen conditions. Proliferation of such cells, which tend to resist chemotherapy and help tumors spread, are considered a major roadblock to successful cancer treatment.
American Cancer Society, Cindy Rosencrans Fund for Triple Negative Breast Cancer, China Scholarship Council

Contact: Catherine Gara
ckolf@jhmi.edu
443-287-2251
Johns Hopkins Medicine

Public Release: 28-Mar-2016
Nature Structural & Molecular Biology
Stressed out: SLU scientist details cells' response to lesions
In the paper, scientist Alessandro Vindigni, Ph.D., details several coping strategies cells use when they face replication stress: the cellular version of choosing yoga, meditation or a trip to the movies after a stressful event.

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University

Public Release: 28-Mar-2016
American Journal of Managed Care
Penn studies show high out-of pocket costs limit access to lifesaving specialty drugs
Specialty drugs have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. But, insurers increasingly require patients to share the high costs of these medications. Two new studies led by researchers at Penn have found evidence that such cost-sharing arrangements are associated with significant reductions in access to these drugs.
Pharmaceutical Research and Manufacturers of America

Contact: Katharine Delach
katie.delach@uphs.upenn.edu
215-349-5964
University of Pennsylvania School of Medicine

Public Release: 28-Mar-2016
Oncotarget
BIDMC researchers discover early indicators of pancreatic cancer
Pancreatic cancer, the fourth leading cause of cancer death in the United States, is often diagnosed at a late stage, when curative treatment is no longer possible. A team led by investigators at Beth Israel Deaconess Medical Center has now identified and validated an accurate 5-gene classifier for discriminating early pancreatic cancer from non-malignant tissue. Described online in the journal Oncotarget, the finding is a promising advance in the fight against this typically fatal disease.
National Institutes of Health, NIH/National Cancer Institute, Ben and Rose Cole Charitable Pria Foundation

Contact: Jennifer Kritz
jkritz@bidmc.harvard.edu
617-667-7301
Beth Israel Deaconess Medical Center

Public Release: 28-Mar-2016
Proceedings of the National Academy of Sciences
Solved: First crystal structure of a transcription terminator protein
Researchers at the Medical University of South Carolina and elsewhere resolve the first protein structure in a family of proteins called transcription terminators that could provide insight into aging and cancer. The work reveals the protein Reb1 to be a traffic signal for coordinating transcription and gene replication, rather than a passive roadblock as previously thought.
NIH/National Institute of General Medical Sciences, South Carolina Clinical & Translational Research Institute, National Institutes of Health, American Cancer Society

Contact: Heather Woolwine
woolwinh@musc.edu
843-792-7669
Medical University of South Carolina

Public Release: 28-Mar-2016
Molecular Cell
Researchers identify SH2 domains as lipid-binding modules for cell signaling
Majority of human Src homology 2 domains not only bind to proteins, but also interact with membrane lipids with high affinity and specificity. The SH2 domain-containing proteins play important roles in various physiological processes and are involved in cancer development. This study reveals how lipids control SH2 domain-mediated cellular protein interaction networks and suggests a new strategy for the therapeutic modulation of pY-signaling pathways.
National Research Foundation of Korea, The World Class University program by the Korean government

Contact: YunMee Jung
ymjung@postech.ac.kr
82-542-792-417
Pohang University of Science & Technology (POSTECH)

Public Release: 27-Mar-2016
Diabetes
New hope for a type 2 diabetes cure
A research team, led by Professor Jang Hyun Choi (School of Life Sciences) of UNIST discovered Gleevec, which is used in leukemia medications, holds promise for a dramatically more effective treatment of type 2 diabetes.
Bio & Medical Technology Development Program of the National Research Foundation, Korean Ministry of Science, ICT and Future Planning

Contact: JooHyeon Heo
joohyeonheo@unist.ac.kr
82-522-171-223
Ulsan National Institute of Science and Technology(UNIST)

Public Release: 25-Mar-2016
Kidney International
Study shows that Wnt secretion preventing drugs may reduce renal fibrosis
Renal fibrosis or the scarring of kidneys, following an injury, reduces their function and can cause kidney disease to progressively worsen. In a recent study, published in Kidney International, researchers from Duke-NUS Medical School (Duke-NUS) in Singapore and Duke University have shown that drugs that target Wnt secretion by inhibiting Porcupine, a protein usually targeted for cancer treatment, may reduce renal fibrosis and protect the kidneys.
Duke/Duke-NUS Research Collaboration Pilot Project Award

Contact: Dharshini Subbiah
dharshini.subbiah@duke-nus.edu.sg
659-616-7532
Duke-NUS Medical School

Public Release: 24-Mar-2016
JAMA Oncology
Economic analysis of PSA screening, selective treatment strategies
Can prostate-specific antigen (PSA) screening for prostate cancer be cost-effective? A study, commentary and author interview published online by JAMA Oncology examines that question.

Contact: Kristin Woodward
kwoodwar@fredhutch.org
206-667-5095
The JAMA Network Journals

Public Release: 24-Mar-2016
ATS supports Osha's more protective crystalline silica exposure standard
While it took nearly three years of waiting, the American Thoracic Society is pleased that OSHA has issued its final rule establishing a more protective standard for occupational silica. The new more protective standard will greatly reduce exposure to this known and potentially deadly occupational hazard.

Contact: Dacia Morris
dmorris@thoracic.org
212-315-8620
American Thoracic Society

Public Release: 24-Mar-2016
Nano Letters
Microneedle patch delivers localized cancer immunotherapy to melanoma
Biomedical engineering researchers have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma skin cancer. In animal studies, the technique more effectively targeted melanoma than other immunotherapy treatments.
National Institutes of Health

Contact: Matt Shipman
matt_shipman@ncsu.edu
919-515-6386
North Carolina State University

Public Release: 24-Mar-2016
Journal of Palliative Medicine
Potential for misuse & diversion of opioids to addicts should not overshadow their therapeutic value
Opioids are very effective for treating some types of pain, such as cancer pain and postoperative pain, but not for other kinds of pain like chronic low back pain. An increase in the number of opioid-related deaths among addicts has led to the current movement to restrict opioid prescribing by state and federal authorities. While a laudable goal, these restrictions threaten to block their use for safe and effective pain relief when medically indicated.

Contact: Kathryn Ryan
kryan@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Showing releases 1151-1175 out of 1382.

<< < 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 > >>

  Search News Releases

     

 

EurekAlert!